Clarity Pharmaceuticals Ltd (ASX:CU6)
Australia · Delayed Price · Currency is AUD 2.100
+0.010 (0.48%)
Sep 17, 2026, 4:10 PM AEST
Clarity Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 4 analysts polled by S&P Global, Clarity Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $7.20. The average 1-year stock price forecast is 242.86% higher than the current stock price, while the lowest is $5.60 (+166.67%) and the highest is $8.41 (+300.48%).
Price Target: $7.20 (+242.86%)
Analyst Consensus: Strong Buy
Price Target
Chart* Price targets were last updated on Aug 11, 2026.
Analyst Ratings
The average analyst rating for Clarity Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Bell Potter | Bell Potter | Buy Maintains $6.40 | Buy | Maintains | $6.40 | +204.76% | Aug 11, 2026 |
| Canaccord Genuity | Canaccord Genuity | Buy Maintains $8.41 | Buy | Maintains | $8.41 | +300.48% | Aug 10, 2026 |
| Jefferies | Jefferies | Buy Maintains $5.60 | Buy | Maintains | $5.60 | +166.67% | Jul 29, 2026 |
Financial Forecast
Revenue This Year
933.33K
from 10.53M
Decreased by -91.13%
Revenue Next Year
61.76M
from 933.33K
Increased by 6,516.81%
EPS This Year
-0.29
from -0.29
EPS Next Year
-0.23
from -0.29
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is AUD.